PEG-ASP+Gemoxd vs. PEG-ASP+CHOP as First-line Chemotherapy to Treatment NK/T-cell Lymphoma With Early Stage

Inclusion Criteria

• •1. pathologically confirmed, previously untreated ENKTL with stage I/II (for stage I, the patients should have one of the following risk factors: EBV-DNA \> upper limit of normal, lesions beyond nasal, fever, LDH elevation);
• •2. age range from 18 to 70 years;
• •3. Eastern Cooperative Oncology Group (ECOG) performance status of 0-2;
• •4. at least one measurable lesion;
• •5. adequate haematologic function (haemoglobin \> 8.0 g/l, absolute neutrophil count \> 1500/ml, platelets \> 75,000/l),
• •6. adequate hepatic function (total serum bilirubin ≤ 1.5 times the upper limit of normal, alanine aminotransferase and aspartate aminotransferase ≤ 2.5 times the upper limit of normal),
• •7. Hepatitis B virus carriers should have normal HBV-DNA copies and should use antiviral drugs. For patients with elevated HBV-DNA, should use antiviral drugs until the HBV-DNA decrease to \< the upper limit of normal.
• •8. adequate renal function (serum creatinine ≤ 1.5 mg/dl, creatinine clearance ≥ 50 ml/min);
• •9. normal coagulation function and electrocardiogram results.
• •10. Prior chemotherapy and radiotherapy should have been completed \>4 weeks earlier,
• •11. willingness to provide written informed consent.
• •2. systematic central nervous system involvement, previous or concomitant malignancies and any coexisting medical problems that could cause poor compliance with the study protocol.
• •3. primary lesion not from the upper respiratory